HOW COULD WE PREVENT TYPE 1 DIABETES ?
DOI:
https://doi.org/10.46793/PP190309003SKeywords:
Type 1 Diabetes, prediction, prevention, autoantibodies, remission, metforminAbstract
Type 1 diabetes mellitus (T1DM) incidence is reaching pandemic proportions, with the most prominent change in the category of the youngest children. Exogenous insulin application is so far unique successful therapy, but permanent cure is still unavailable. It is an example of multifactorial autoimmune disease, resulting from complex interplay of genetic, endogenous and environmental factors. The pressure of exogenous, preventable factors is evident and responsible for the increasing incidence. Primary prevention by identification and elimination of environmental triggers that included eradication of maternal viral infection or nutrient modulation, optimal vitamin D intake, oral induction of tolerance to insulin, was unfortunately inefficient.New biomarkers for diabetes prediction will allow development of more successful prevention strategies. Autoantibodies detection at age of 3 years, in children from susceptible families discovers candidates for new interventional studies. Remission phase in T1DMis period favorable for secondary prevention with the use of insulin sensitizer, metformin.
References
Fonolleda M. Murillo M, Vazquez F, Bel J, Vives-Pi M. Remission phase in pediatric Type 1 diabetes: new understanding and emerging biomarkers. Horm Res Paediatr 2017; 88: 307-315.
Rewers M. Pathogenesis of type 1 diabetes: environmental factors. International Diabetes Monitor. 2010;22:112-20.
Meier JJ. Beta cell mass in diabetes: a realistic therapeutic target ? Diabetologia. 2008;51;703-
Tsai EB, Sherry NA, Palmer JP, Herold KC for the DPT-1 Study Group. The rise and fall of insulin secretion in type 1 diabetes mellitus. Diabetologia. 2006;49:261-70.
Dahlquist G. Can we slow the rising incidence of childhood-onset autoimmune diabetes? The overload hypothesis. Diabetologia 2006;49:20-4.
Wilkin TJ. The accelerator hypothesis: weight gain as a missing link between type I and type II diabetes. Diabetologia. 2001; 44: 914-22.
Wilkin TJ. Changing perspectives in diabetes: their impact on its classification. Diabetologia. 2007; 50:1587-92.
Imagawa A, Hanafusa T, Miyagawa J, Matsuzava Y. A novel subtype of type 1 diabetes mellitus characterized by a rapid onset and an absence of diabetes-related antibodies. Osaka IDDM Study Group. N Engl J Med. 2000; 342:301-7.
Wang I, Wang F-S, Gershwin ME. Human autoimmune diseases; a comprehensive update. J intern Med 2015; 278: 369-395
Michels A, Zhang L, Khadra A, Kushner JA, Redondo MJ, Pietropaolo M. Prediction and prevention of Type 1 diabetes: update on success of prediction and struggles at prevention. Pediatric Diabetes 2015; 16(7): 465-484
Paschou SA, papadopoulou-Marketou N, Chrousos GP, Kanaka-Gantenbein K. On Type 1 diabetes mellitus pathogenesis (Review). Endocrine Connections 2018; 7 (1): 38-46.
Perheentupa J.APS-I/APECED: the clinical disease and therapy. Endocrinol Metab Clin North Am 2002; 31: 295-320.
Saranac L, Samardžic M. Diabetes mellitus in childhood; facts and controversies.(Review) Paediatrics Today 2011; 7(1): 10-17.
Gillespie KM. Type 1 diabetes: pathogenesis and prevention. CMAJ 2006; 175(2): 165-70.
Jacobsen LM, Haller MJ, Schatz DA. Understanding pre-type 1 diabetes: the key to prevention. Front in Endocrinol 2018; 9 art 70: 1-8.
Michels AW., Gottlieb PA. Learning from past failures of oral insulin trials. Diabetes 2018; 67: 1211-1215.
Imam S, Prathibha R, Dar P, Alotah K Al-Khudhair A, Abdul-Moiz S et al. EIF5A inhibition influences T cell dynamics in the pancreatic microenvironment of the humanized mouse model of Type 1 diabetes. Scientific Reports 2019; 9(1): DOI: 10.1038/s41598-018-38341-5
Ostrov DA, Alkanani A, McDaniel KA. Case S, Baschal EE, Pyle L, et al. Methyldopa blocks MHC class II binding to disease-specific antigens in autoimmune diabetes. J Clin Invest 2018; 128: 1888-1902.
Raab J, Haupt F, Scholtz M, Matzke K, Warncke K, Lange K et al. Capillary blood islet autoantibody screening for identifying pre-type 1 diabetes in the general population: design and initial results of the Fr1da study. BMJ Open 2016;6: e011144, DOI: 10.1136/bmjopen-2016-011144
Wilkin TJ. The accelerator hypothesis: weight gain as a missing link between type I and type II diabetes. Diabetologia. 2001; 44: 914-22.
Wilkin TJ. Changing perspectives in diabetes: their impact on its classification. Diabetologia. 2007; 50:1587-92.
Wilkin TJ. The great weight gain experiment, accelerators and their implications for autoantibodies in diabetes. Arh Dis Child. 2006;91:456-8.
Wilkin TJ. The accelerator hypothesis-an evolving concept. Facta Univ Ser Med Biol 2015; 17(2): 49-53
Saranac L, Zivanovic S, Kostic G, Bjelakovic B, Novak M. Combined treatment in childhood diabetes could influence remission period. Abstr European Congress of Endocrinology 2009, Istanbul. Endocrine Abstracts. 2009;20: 382.
Saranac L, Bjelakovic B, Zivanovic S, Novak M. Intervention with metformin in childhood diabetes may slow decline of C peptide - the accelerator hypothesis. Abstr 46th Ann Meet EASD, Stocholm, 2010. Diabetologia. 2010;53 (Suppl 1): S 372.
Livingstone R, Boyle JG, Petrie JR. on behalf of The REMOVAL study team. A new perspective on metformin therapy in type 1 diabetes. Diabetologia 2017; 60: 1594-1600.
Denroche HC, Nackiewicz D, Verchere CB. When beta cells talk back. Diabetologia 2018; 61: 39-42.
Sims E, Evans-Molina, Tersey SA, Eizirik DL, Mirmira RG. Biomarkers of beta cell stress and death in type 1 diabetes. Diabetologia 2018; 61; 2259-2265.
Mathieu Chantal, Lahesmaa R, Bonifacio E, Achenbach P, Tree T. Immunological biomarkers for the development and progression of type 1 diabetes. Diabetologia 2018; 61: 2252-2258.
